From innovation to therapeutic care
Go faster for Sickle Cell Disease patients



A based-Genopole company founded on breakthrough innovation, 

INNOVHEM is developing solutions that will both promote the development and optimization of use of treatments for the most common genetic disease over the world, sickle cell disease.


Our Mission

Transform clinical care to improve patients quality of life

Our proposition

Combining innovative biomarkers with AI

Combining biomarkers adapted to Red Blood Cell diseases with AI, 

INNOVHEM is developping solutions, which make possible to optimize the care of patients: 

  • Improving the development of effective treatments

  • Offering personalized therapy for each patients

The Biomarkers

 Fetal Hemoglobin per Red Blood Cell

- Related to the pathophysilogy of Sickle Cell Disease
- Accurate

A new method to dose intra-vascular hemolysis

- Direct

- Accurate

The Team

A leadership on Sickle Cell Disease

Marie Cambot

Laura Bencheikh

Project Manager

Ils nous soutiennent

Région Ile de France

Evry, Région Ile de France



  • INNOVHEM is very pleased to announce the start of a preclinical Investigator Sponsored Trial with funding support by Jazz Pharmaceuticals, to support the development of new treatments for sickle cell disease

November, 27, 2020

©2019 by INNOVHEM. Proudly created with Wix.com

This site was designed with the
website builder. Create your website today.
Start Now